Prothena Corporation plc
HealthcareNASDAQ:PRTA · NASDAQ Global Select
-$0.01 today
Vol 0.29M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.0%
avg -34.9%
ROIC
-63.9%
avg -28.1%
ROA
-74.7%
avg -26.6%
Analysis
ROIC is currently the strongest return metric at -63.9% versus its period average of -28.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gene G. Kinney | President, Chief Executive Officer & Director | $1.12M | — | 57 | $520,000.00 | 0.99% |
Tran Nguyen | Chief Financial Officer | $916,334.00 | — | 52 | $230,000.00 | 0.44% |
Brandon S. Smith | Chief Operating Officer | $826,819.00 | — | 51 | $190,000.00 | 0.36% |
Chad Swanson | Chief Development Officer | $739,084.00 | — | — | $190,000.00 | 0.36% |
Wagner Zago | Chief Scientific Officer | $735,660.00 | — | 53 | $190,000.00 | 0.36% |
Michael J. Malecek | Chief Legal Officer & Company Secretary | $588,250.00 | — | 60 | $0.00 | <0.01% |
Mark C. Johnson | Vice President of Investor Relations | — | — | — | — | — |
Annie Evans Kingston | Chief Strategy Officer | — | — | — | $0.00 | <0.01% |
Karin L. Walker | Chief Accounting Officer & Controller | — | — | 63 | $150,000.00 | 0.29% |
Phillip Dolan | Sr. Director & Head of Exploratory Research | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$2.94M
Sells
0
$0.00
Net Sentiment
+$2.94M
Net buying
Most Active
SCULLY WILLIAM P
4 transactions
Analysis
Insiders reported 4 buys worth $2.94M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.94M. SCULLY WILLIAM P was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -15.4% | +40.6% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -15.4% over three years. Forward estimates point to Revenue at +40.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages PRTA?
Prothena Corporation plc (PRTA) lists 10 active executives. The top listed executive is Tran Nguyen, Chief Financial Officer.
Are PRTA insiders buying or selling?
Recent insider activity shows net buying of $21.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.